Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Deferasirox
Drug: Cholecalciferol
Drug: Azacitidine

First Posted Date: 2015-01-19

Last Posted Date: 2020-02-27

Lead Sponsor: Elizabeth Henry

Target Recruit Count: 4

Registration Number: NCT02341495

Locations: 🇺🇸
Loyola University Cardinal Bernardin Cancer Center, Maywood, Illinois, United States

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

Phase 4

Withdrawn

Conditions: Thalassemia (Transfusion Delendent)

Interventions: Drug: deferasirox

First Posted Date: 2014-02-24

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02069886

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Phase 2

Withdrawn

Conditions: Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD

Interventions: Drug: Deferasirox

First Posted Date: 2013-09-24

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01948817

Treatment of Iron Overload Requiring Chelation Therapy

Phase 2

Withdrawn

Conditions: Beta-thalassemia
Metabolic Diseases
Transfusional Iron Overload
Iron Overload
Iron Chelation
Iron Metabolism Disorders
Transfusional Hemosiderosis

Interventions: Drug: SPD602
Drug: Deferasirox

First Posted Date: 2013-08-23

Last Posted Date: 2021-06-02

Lead Sponsor: Shire

Registration Number: NCT01927913

Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox

Completed

Conditions: Iron Overload
Thalassemia

Interventions: Drug: Deferasirox

First Posted Date: 2013-07-23

Last Posted Date: 2015-09-01

Lead Sponsor: HaEmek Medical Center, Israel

Target Recruit Count: 36

Registration Number: NCT01905774

Locations: 🇮🇱
Ha'Emek Medical Center, Afula, Israel

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes
Hemochromatosis

Interventions: Other: Venesection
Drug: Deferasirox

First Posted Date: 2013-07-04

Last Posted Date: 2024-04-03

Lead Sponsor: Haukeland University Hospital

Registration Number: NCT01892644

Locations: 🇳🇴
Haukeland University Hospital, Clinical Trial Unit, Bergen, Norway

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Phase 3

Completed

Conditions: Chronic Iron Overload

Interventions: Drug: Deferiprone
Drug: Deferasirox

First Posted Date: 2013-04-05

Last Posted Date: 2021-05-04

Lead Sponsor: Consorzio per Valutazioni Biologiche e Farmacologiche

Target Recruit Count: 435

Registration Number: NCT01825512

Locations: 🇪🇬
Cairo University Faculty of Medicine, Cairo, Egypt
🇪🇬
Zagazig University Hospitals, Zagazig, Egypt
🇦🇱
Hospital 'Ihsan Çabej', Lushnjë, Albania

and more 19 locations

An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

Phase 4

Withdrawn

Conditions: β-thalassemia Major

Interventions: Drug: Deferasirox

First Posted Date: 2012-11-09

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01724138

Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia

Phase 4

Completed

Conditions: Non-transfusion Dependent Thalassemia

Interventions: Drug: deferasirox

First Posted Date: 2012-10-18

Last Posted Date: 2019-10-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 134

Registration Number: NCT01709838

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Phase 2

Terminated

Conditions: Transfusion-dependent β-thalassemia Patients
Cardiac Iron Overload

Interventions: Drug: Deferasirox
Drug: Deferoxamine (DFO)

First Posted Date: 2011-10-26

Last Posted Date: 2019-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01459718

Locations: 🇬🇷
Novartis Investigative Site, Patras, Greece

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy